@rhondaswan's peptide biohacking claims, fact-checked

What did @rhondaswan actually say?

This is a short Instagram clip from a biohacking event in Tampa, featuring Jay Campbell, who describes himself as a peptide expert. The conversation covers GLP-1 peptides for metabolic health, the importance of hormone optimization before starting peptides, and the problem of muscle loss on GLP-1 drugs. Then it goes somewhere much bolder: Campbell claims that Klotho, described as "a revolution in an endocrine protein responsible for pretty much all the cellular aging processes," will be available by injection within three to four months and will "dramatically lower your age" and slow telomere aging with just one or two injections per month.

He also warns that most GLP-1 users are not getting good advice, losing muscle mass, and developing what he calls "wiggledy face" and "wiggledy neck." He plugs a documentary and an upcoming book called Metabolic Awakening.

Does the science back this up?

The GLP-1 muscle loss warning is grounded in real evidence. The Klotho injection claim is not, at least not yet.

On GLP-1s: the concern about lean mass loss is well-documented. A 2022 trial published in Obesity by Wilding et al. found that semaglutide-treated patients lost significant fat mass but also meaningful lean mass, particularly without resistance training and adequate protein. Campbell's point that people are being undertaught on protein intake and exercise is a legitimate clinical concern echoed by endocrinologists regularly.

On Klotho: the biology is real and interesting. Klotho is a protein that declines with age and has been linked to longevity in animal studies. Research by Kuro-o et al. published in Nature (1997) originally identified Klotho knockout mice as aging rapidly, which launched decades of investigation. More recent work by Dubal et al. (2014, Cell Reports) showed exogenous Klotho improved cognitive function in mice. But none of this translates to a commercially available human injection product arriving in three to four months. There are no approved human Klotho therapies, and clinical trials in humans are extremely limited.

What did they get wrong (or right)?

Campbell gets real credit for the GLP-1 muscle loss warning. The "skinny shot" framing that ignores protein intake and resistance training is a genuine public health problem. Saying "people stop eating, they don't get enough protein" is accurate, blunt, and something more practitioners should be saying out loud.

His point that hormonal deficiencies need to be addressed before peptides will work optimally is a reasonable clinical perspective, though not universally established in controlled trials. It reflects a common integrative medicine approach but should not be presented as settled science.

Where this falls apart: the Klotho injection claim is irresponsible. Saying it will "dramatically lower your age" and will be available in three to four months as an injectable has no clinical trial basis in humans. There is no approved or near-approved exogenous Klotho product. Presenting this to 74,000 viewers as imminent and near-certain is misleading, regardless of how exciting the preclinical data might be. "Blue ocean opportunity" framing around unproven longevity injections should raise flags for any viewer.

What should you actually know?

GLP-1 receptor agonists like semaglutide are FDA-approved medications with real evidence for weight loss and metabolic benefit, but the muscle loss risk is real and often underdiscussed. A 2023 review in The New England Journal of Medicine by Kushner et al. emphasized that behavioral support, protein targets, and resistance training are necessary companions to GLP-1 therapy, not optional extras.

Klotho research is genuinely exciting in preclinical models. But exciting mouse data has failed to translate to humans hundreds of times in aging research. No exogenous Klotho injection product for humans is in late-stage clinical trials as of 2024. Anyone claiming otherwise, or claiming a release window, is speculating well beyond what the data supports.

• If you are considering GLP-1 therapy, ask your provider specifically about protein intake targets and whether resistance training was discussed.
• Hormone optimization before peptide therapy is a reasonable conversation to have with a licensed provider, but it is not a universal prerequisite proven in randomized trials.
• Be skeptical of any influencer announcing specific timelines for unproven longevity injections at a biohacking event.